

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/002913

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ C07D209/08, A61K31/4045, A61P9/00, 13/10, 19/00, 25/02, 25/16,
25/28, 43/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ C07D209/08, A61K31/4045, A61P9/00, 13/10, 19/00, 25/02, 25/16,
25/28, 43/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAPLUS (STN), CAOLD (STN), REGISTRY (STN), MEDLINE (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 2001-288115 A (Yamanouchi Pharmaceutical Co., Ltd.), 16 October, 2001 (16.10.01), & CA 2435989 A & WO 2002/062390 A1 & EP 1358889 A1 & US 2004/072851 A1	1-5
Y	JP 2000-247998 A (Kissei Pharmaceutical Co., Ltd.), 12 September, 2000 (12.09.00), (Family: none)	1-5
Y	WO 99/15202 A1 (Kissei Pharmaceutical Co., Ltd.), 01 April, 1999 (01.04.99), & AU 9890959 A1	1-5

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
31 March, 2005 (31.03.05)Date of mailing of the international search report
19 April, 2005 (19.04.05)Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Patent provided by Sughrue Mion, PLLC, http://www.sughrue.com

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2005/002913

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/48530 A1 (MERCK & CO., INC.), 30 September, 1999 (30.09.99), & AU 9930112 A1 & US 6410554 B1	1-5
Y	US 2002/143007 A1 (GARVEY, D.S.), 03 October, 2002 (03.10.02), & US 5932538 A & US 5994294 A & US 6294517 B1	1-5
Y	YAMADA, S., "In vivo receptor binding of novel <SYM97>1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia, Life Sciences, 1998 Nen, Vol.62, No.17/18, pages 1585 to 1589	1-5
Y	OKURA, T., "Selective and sustained occupancy of prostatic <SYM97>1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats", Journal of Pharmacy and Pharmacology, 2002 Nen, Vol.54, No.7, pp. 975-98	1-5
Y	AKIYAMA, K., "Effects of KMD-3213, a uroselective <SYM97>1A-adrenoceptor antagonist on the tilt-induced blood pressure response in normotensive rats", Japanese Journal of Pharmacology, 2002 Nen, Vol.90, No.2, pages 131 to 137	1-5
Y	Teruhisa OHASHI, Shinryo Kenkyu, "Hainyo Shogai to Nyo Shikkin (Ge)", Gekkan Hodanren, 1998 Nen, No.591, pages 57 to 60	1-5
Y	Masataka YOSHIDA, "Kabu Nyoro Kino Kenkyu no Saikin no Shinpo: Kiso Kenkyu o Rinsho Oyo ni Tsugu 3 Kabu Nyoro Heikatsukin Kino ni Kakawaru Shinkei Dentatsu Busshitsu no Yakurigakuteki Bunseki", Folia Pharmacologica Japonica, 2003 Nen, Vol.121, No.5, pages 307 to 316	1-5
Y	Osamu ISHIDUKA, "Koreisha no Zenritsusen Shikkan Zenritsusen Shikkan to Kakatsudo Boko", Geriatr Med, 2003 Nen, Vol.41, No.8, pages 1149 to 1153	1-5
Y	ISHIZUKA O., Micturition in conscious rats with and without bladder outlet obstruction: role of spinal α 1-adrenoceptors., Br.J.Pharmacol., 1996 Nen, Vol.117, No.5, pages 962 to 966	1-5
P,X	WO 2004/054574 A1 (Kissei Pharmaceutical Co., Ltd.), 01 July, 2004 (01.07.04),	1-5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2005/002913

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2004/022538 A1 (Kissei Pharmaceutical Co., Ltd.), 18 March, 2004 (18.03.04),	1-5

(12)特許協力条約に基づいて公開された国際出願

(19)世界知的所有権機関
国際事務局



(43)国際公開日
2005年9月15日 (15.09.2005)

PCT

(10)国際公開番号
WO 2005/085195 A1

(51)国際特許分類7: C07D 209/08, A61K 31/4045, A61P 9/00, 13/10, 19/00, 25/02, 25/16, 25/28, 43/00

穂高町大字柏原 4365-1 キッセイ薬品工業株式会社中央研究所内 Nagano (JP).

(21)国際出願番号: PCT/JP2005/002913

(81)指定国(表示のない限り、全ての種類の国内保護が可能): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22)国際出願日: 2005年2月23日 (23.02.2005)

(84)指定国(表示のない限り、全ての種類の広域保護が可能): ARPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), ヨーラシア (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25)国際出願の言語: 日本語

添付公開書類:
— 國際調査報告書

(26)国際公開の言語: 日本語

2文字コード及び他の略語については、定期発行される各PCTガゼットの巻頭に掲載されている「コードと略語のガイドノート」を参照。

(30)優先権データ:
特願2004-061476 2004年3月5日 (05.03.2004) JP


(71)出願人(米国を除く全ての指定国について): キッセイ薬品工業株式会社 (KISSEI PHARMACEUTICAL CO., LTD.) [JP/JP]; 〒3998710 長野県松本市芳野19番4号 Nagano (JP).

(72)発明者、および

(75)発明者/出願人(米国についてのみ): 山崎 芳伸 (YAMAZAKI, Yoshinobu) [JP/JP]; 〒3998304 長野県南安曇郡穂高町大字柏原 4365-1 キッセイ薬品工業株式会社中央研究所内 Nagano (JP). 今村 卓広 (IMAMURA, Takahiro) [JP/JP]; 〒3998304 長野県南安曇郡

(54)Title: MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF OVERACTIVE BLADDER ACCOMPANYING NERVOUS DISORDER

(54)発明の名称: 神経障害に伴う過活動膀胱の予防または治療用医薬組成物



(I)

cerebrovascular disorder, Parkinson's disease, and myelopathy. In the formula, R represents optionally substituted aliphatic acyl, optionally substituted lower alkyl, optionally substituted aromatic acyl, etc.; R¹ represents cyano or carbamoyl; and R² represents optionally substituted lower alkyl.

(57)Abstract: A medicinal composition for the prevention or treatment of overactive bladder accompanying nervous disorders. The medicinal composition contains as an active ingredient an indoline derivative represented by the following general formula (I) or a pharmacologically acceptable salt thereof. The medicinal composition is useful in the prevention or treatment of overactive bladder accompanying nervous disorders such as

(57)要約: 神経障害に伴う過活動膀胱を予防又は治療するための医薬組成物を提供する。下記一般式(I)で表されるインドリン誘導体またはその薬理学的に許容される塩を有効成分として含有する医薬組成物。該医薬組成物は、脳血管障害、パーキンソン病、脊髄障害等の神経障害に伴う過活動膀胱の予防又は治療に有用である。式中のRは置換可脂肪族アシル基、置換可低級アルキル基、置換可芳香族アシル基等、R¹はシアノ基又はカルバモイル基、R²は置換可低級アルキル基を表す。

WO 2005/085195 A1